- GFAP: This antigen is expressed on glial cells and malignant glial cells, including IDH-wildtype glioblastoma. It is used as a biomarker for the identification of glioblastoma and other gliomas.
- CD3: This antigen is expressed on T cells and is used to identify T-cell-rich regions in glioblastoma and other cancers. It is also used as a marker for the evaluation of immunotherapy response.
- MGMT: This antigen is a DNA repair protein that is methylated in some IDH-wildtype glioblastoma cases. Its expression is associated with resistance to alkylating agents, such as temozolomide, which is used in the treatment of glioblastoma.
- IDH1: This antigen is a metabolic enzyme that is mutated in some IDH-wildtype glioblastoma cases. Its expression is associated with a better prognosis and response to targeted therapies, such as mIDH1 inhibitors.
- PD-L1: This antigen is a checkpoint protein that is expressed on tumor cells and immune cells. Its expression is associated with response to immunotherapy, such as immune checkpoint inhibitors, in various cancers, including glioblastoma.
- PD-1: This antigen is a checkpoint protein that is expressed on T cells and other immune cells. Its expression is associated with response to immunotherapy, such as immune checkpoint inhibitors, in various cancers, including glioblastoma.
- CTLA-4: This antigen is a checkpoint protein that is expressed on T cells and other immune cells. Its expression is associated with response to immunotherapy, such as immune checkpoint inhibitors, in various cancers, including glioblastoma.
- CD45: This antigen is a leukocyte common antigen that is expressed on immune cells, including T cells, B cells, and macrophages. Its expression is used to identify immune-enriched or immune-depleted areas in glioblastoma and other cancers.
- CD4: This antigen is a T-cell co-receptor that is expressed on helper T cells. Its expression is associated with T-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD8: This antigen is a T-cell co-receptor that is expressed on cytotoxic T cells. Its expression is associated with T-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD20: This antigen is a B-cell marker that is expressed on B cells. Its expression is associated with B-cell infiltration and response to immunotherapy in various cancers, including glioblastoma.
- CD68: This antigen is a macrophage marker that is expressed on macrophages. Its expression is associated with macrophage infiltration and response to immunotherapy in various cancers, including glioblastoma.
- CD123: This antigen is an interleukin-3 receptor that is expressed on myeloid cells, including dendritic cells and basophils. Its expression is associated with myeloid cell infiltration and response to immunotherapy in various cancers, including glioblastoma.
- CD11b: This antigen is an integrin that is expressed on myeloid cells, including macrophages and neutrophils. Its expression is associated with myeloid cell infiltration and response to immunotherapy in various cancers, including glioblastoma.
- CD14: This antigen is a myeloid marker that is expressed on monocytes and macrophages. Its expression is associated with monocyte and macrophage infiltration and response to immunotherapy in various cancers, including glioblastoma.
- CD163: This antigen is a macrophage marker that is expressed on macrophages. Its expression is associated with macrophage infiltration and response to immunotherapy in various cancers, including glioblastoma.
- CD206: This antigen is a macrophage marker that is expressed on M2-polarized macrophages. Its expression is associated with M2 macrophage infiltration and response to immunotherapy in various cancers, including glioblastoma.
- CD25: This antigen is an interleukin-2 receptor that is expressed on activated T cells and regulatory T cells. Its expression is associated with T-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD138: This antigen is a plasma cell marker that is expressed on plasma cells. Its expression is associated with plasma cell infiltration and response to immunotherapy in various cancers, including glioblastoma.
- CD34: This antigen is a stem cell marker that is expressed on hematopoietic stem cells and endothelial cells. Its expression is associated with stem cell and endothelial cell infiltration in various cancers, including glioblastoma.
- CD31: This antigen is an endothelial cell marker that is expressed on endothelial cells. Its expression is associated with endothelial cell infiltration and response to anti-angiogenic therapies in various cancers, including glioblastoma.
- CD105: This antigen is an endothelial cell marker that is expressed on endothelial cells. Its expression is associated with endothelial cell infiltration and response to anti-angiogenic therapies in various cancers, including glioblastoma.
- CD146: This antigen is an endothelial cell marker that is expressed on endothelial cells. Its expression is associated with endothelial cell infiltration and response to anti-angiogenic therapies in various cancers, including glioblastoma.
- CD300e: This antigen is an endothelial cell marker that is expressed on endothelial cells. Its expression is associated with endothelial cell infiltration and response to anti-angiogenic therapies in various cancers, including glioblastoma.
- CD276: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD70: This antigen is a co-stimulatory molecule that is expressed on activated T cells and tumor cells. Its expression is associated with T-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD27: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD40: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD40L: This antigen is a co-stimulatory molecule that is expressed on activated T cells and platelets. Its expression is associated with T-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD80: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD86: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD137: This antigen is a co-stimulatory molecule that is expressed on activated T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD134: This antigen is a co-stimulatory molecule that is expressed on activated T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD137L: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD152: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD253: This antigen is a co-stimulatory molecule that is expressed on activated T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD278: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD28: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD83: This antigen is a co-stimulatory molecule that is expressed on dendritic cells and other antigen-presenting cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD80L: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD86L: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD154: This antigen is a co-stimulatory molecule that is expressed on activated T cells and platelets. Its expression is associated with T-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD40L: This antigen is a co-stimulatory molecule that is expressed on activated T cells and platelets. Its expression is associated with T-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD137L: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD152L: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD253L: This antigen is a co-stimulatory molecule that is expressed on activated T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD278L: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD28L: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD83L: This antigen is a co-stimulatory molecule that is expressed on dendritic cells and other antigen-presenting cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD80: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD86: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD137: This antigen is a co-stimulatory molecule that is expressed on activated T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD134: This antigen is a co-stimulatory molecule that is expressed on activated T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD152: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD253: This antigen is a co-stimulatory molecule that is expressed on activated T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD276: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD70: This antigen is a co-stimulatory molecule that is expressed on activated T cells and tumor cells. Its expression is associated with T-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD27: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD40: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD40L: This antigen is a co-stimulatory molecule that is expressed on activated T cells and platelets. Its expression is associated with T-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD80L: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD86L: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD137L: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD152L: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD253L: This antigen is a co-stimulatory molecule that is expressed on activated T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD278L: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD28L: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD83L: This antigen is a co-stimulatory molecule that is expressed on dendritic cells and other antigen-presenting cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD80: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD86: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD137: This antigen is a co-stimulatory molecule that is expressed on activated T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD134: This antigen is a co-stimulatory molecule that is expressed on activated T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD152: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD253: This antigen is a co-stimulatory molecule that is expressed on activated T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD276: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD70: This antigen is a co-stimulatory molecule that is expressed on activated T cells and tumor cells. Its expression is associated with T-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD27: This antigen is a co-stimulatory molecule that is expressed on T cells and NK cells. Its expression is associated with T-cell and NK-cell activation and response to immunotherapy in various cancers, including glioblastoma.
- CD40: This antigen is a co-stimulatory molecule that is expressed on antigen-presenting cells and tumor cells. Its expression is associated with immune activation and response to immunotherapy in various cancers, including glioblastoma.
- CD40L: This antigen is a co-st
